

## Important Update: Monoclonal Antibody Treatment

The Food and Drug Administration is no longer authorizing Bebtelovimab as a treatment for COVID-19 as of November 30, 2022, because it is not expected to neutralize Omicron sub-variants BQ.1 and BQ.1.1.

### CPT Codes for Monoclonal Antibody Therapy

The table below provides a list of monoclonal antibody treatments covered by Florida Blue. Please review the effective dates as some of these treatments no longer have emergency use authorization and are not covered, including Bebtelovimab.

HCPSC Code	HCPSC Short Descriptor	Labeler Name	National Payment Allowance Effective for Claims with DOS on or after 05/6/2021	Effective Dates
Q0249	Tocilizumab for COVID-19	Genentech	\$6.57	06/24/2021 – TBD
M0249	Adm Tocilizu COVID-19 1st	Genentech	\$450.00 <sup>[1]</sup>	06/24/2021 – TBD
M0250	Adm Tocilizu COVID-19 2nd	Genentech	\$450.00 <sup>[2]</sup>	06/24/2021 – TBD
<b>The medications below are no longer covered as they no longer have emergency use authorization.</b>				
M0239	Bamlanivimab-xxxx infusion	Eli Lilly	Code not active during this time period	11/10/2020 – 04/16/2021
M0240	Casiri and imdev repeat	Regeneron	\$450.00 <sup>[1]</sup>	07/30/2021 – 01/24/2022
M0241	Casiri and imdev repeat hm	Regeneron	\$750.00 <sup>[2]</sup>	07/30/2021 – 01/24/2022
M0243	Casirivi and imdevi inj	Regeneron	\$450.00 <sup>[2]</sup>	11/21/2020 – 01/24/2022
M0244	Casirivi and imdevi inj hm	Regeneron	\$750.00 <sup>[2]</sup>	05/06/2021 – 01/24/2022
M0245	Bamlan and etesev infusion	Eli Lilly	\$450.00 <sup>[2]</sup>	02/09/2021 – 01/24/2022
M0246	Bamlan and etesev infus home	Eli Lilly	\$750.00 <sup>[2]</sup>	05/06/2021 – 01/24/2022
M0247	Sotrovimab infusion	GSK	\$450.00 <sup>[2]</sup>	05/26/2021 – 04/05/2022
M0248	Sotrovimab inf, home admin	GSK	\$750.00 <sup>[2]</sup>	05/26/2021 – 04/05/2022

<b>Q0239</b>	Bamlanivimab-xxxx	Eli Lilly	Code not active during this time period	11/10/2020 – 04/16/2021
<b>Q0240</b>	Casirivi and imdevi 600mg	Regeneron	\$0.010 <sup>[1]</sup>	07/30/2021 – 01/24/2022
<b>Q0243</b>	Casirivimab and imdevimab	Regeneron	\$0.010 <sup>[1]</sup>	11/21/2020 – 01/24/2022
<b>Q0244</b>	Casirivi and imdevi 1200 mg	Regeneron	\$0.010 <sup>[1]</sup>	06/03/2021 – 01/24/2022
<b>Q0245</b>	Bamlanivimab and etesevima	Eli Lilly	\$0.010 <sup>[1]</sup>	02/09/2021 – 01/24/2022
<b>Q0247</b>	Sotrovimab	GSK	\$2,394.00	05/26/2021 – 04/05/2022
<b>Q0222</b>	Bebtelovimab 175 mg	Eli Lilly	\$2,394.00 <sup>[2]</sup>	02/11/2022 – 11/30/2022
<b>M0222</b>	Bebtelovimab injection	Eli Lilly	\$350.50 <sup>[2]</sup>	02/11/2022 – 11/30/2022
<b>M0223</b>	Bebtelovimab injection home	Eli Lilly	\$550.50 <sup>[2]</sup>	02/11/2022 – 11/30/2022

Visit [CMS's website](#) for more information on payment allowances and effective dates for COVID-19 Vaccines and Monoclonal Antibodies during the Public Health Emergency.

### Billing Information

For Commercial plan patients, if your facility provides monoclonal antibody treatment for COVID-19, please bill Florida Blue for covered infusion therapy for the **administration and the drug purchased commercially through the manufacturer** using the appropriate CPT code. If the drug is supplied by the government, **only** the administration should be billed. Your Florida Blue patients will be responsible for their normal cost share. You can check patient eligibility and benefits through Availity<sup>®3</sup> on [availity.com](https://www.availity.com).

For Medicare Advantage plan patients treated on or after January 1, 2022 (except for most Medicare Advantage hospice patients), submit claims for **administering** COVID-19 monoclonal antibody products to Florida Blue Medicare. Original Medicare stopped paying these claims starting January 1, 2022.

<sup>1</sup>Providers should not bill for the product if they received it for free.

<sup>2</sup>These rates will be geographically adjusted for many providers. For providers and suppliers with payments that are geographically adjusted by the methodology used by the Medicare Physician Fee Schedule (MPFS), files with the geographically adjusted payment rates for monoclonal antibody administration are included in the “Additional Resources” section below. Certain settings utilize other payment methodologies, such as payment based on reasonable costs.

<sup>3</sup>Availity, LLC is a multi-payer joint venture company. For more information or to register, visit [availity.com](https://www.availity.com).

Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.